(NASDAQ: RXST) Rxsight's forecast annual revenue growth rate of 3.18% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 12.34%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 56.5%.
Rxsight's revenue in 2026 is $142,086,000.On average, 13 Wall Street analysts forecast RXST's revenue for 2026 to be $5,690,954,142, with the lowest RXST revenue forecast at $5,314,736,886, and the highest RXST revenue forecast at $6,267,409,435. On average, 11 Wall Street analysts forecast RXST's revenue for 2027 to be $6,243,150,618, with the lowest RXST revenue forecast at $5,681,497,315, and the highest RXST revenue forecast at $6,856,610,886.
In 2028, RXST is forecast to generate $6,704,068,152 in revenue, with the lowest revenue forecast at $6,294,135,251 and the highest revenue forecast at $7,058,904,755.